Axon Enterprise, Inc. · Industrials
The price already needs more growth than analysts forecast, at both a 9% and an 8% discount rate.
At a 10.0% margin the price requires 30.5% 3y revenue CAGR against consensus 28.5%; cushion -22.7pt (-18.3pt at 1pt lower r) versus a 3pt correction cut. Story broke before the drop on cash conversion; AI correction is not the cause. Market: company drawdown (-55% from peak), trend broken.
Would recover if: Litigation overhang escalates or SBC stays near 18% of revenue with no GAAP margin step-up.. We re-check this against analyst estimates every evening.
10 years, at a 10% margin (analysts' margin, cut for cash conversion)
+17.7%/yr over 10 years once faded to terminal growth
points off 3-year analyst growth
8 published targets, set before the drop
Does the profit analysts build their margin on actually arrive as cash? Measured over the last 3 annual statements filed before this test. After stock-based pay, 0% of reported profit arrived as operating cash, so the test cuts the analysts' 19% margin to 10%. That leaves a cushion of −24pt instead of −6pt, and the smaller of the two decides the group. Two or more red flags: this name cannot come out on top, however large its cushion.
How much of reported profit arrived as operating cash. Below 0.8× is a red flag.
Profit not backed by cash, as a share of assets, latest year. Above 10% is a red flag.
Staff paid in shares instead of cash, which flatters margins. Above 10% is a red flag.
Dilution of each share's claim on the business. Above 3% a year is a red flag.
Non-operating gains in the latest year. Above 25% is a red flag.
After capex. Shown for context: heavy investment is not bad earnings, so it is never solved under.
From the priced-in reconstruction of Sep 13, 2026. Its figures use that day's price and free-cash-flow margin, so they can differ from the stress test above.
The price sits 32% below the median published target and at the very bottom of the $600–$750 model range, meaning the market has fully absorbed the current 30-35% revenue growth but explicitly refuses to pay for the acceleration to 50%+ growth that the valuation math requires.
Can Axon sustainably accelerate its revenue growth above 50% annually for the next decade, and can it convert its headline profitability into actual free cash flow—questions that the available wired data (unit volumes) can only partially answer by tracking whether the top-line acceleration actually materializes.
What the price refuses to pay for, and the full reconstruction, on the AXON quote page →A stress test of whether this narrative is still paid for by analyst forecasts, not a forecast that the stock will rise. The price-implied growth on its own has not predicted returns in our testing, and this list (sealed Nov 21, 2026) has not been graded yet. Cut sizes are assumptions. Not investment advice. Back to all names